Two experimental drugs can buy precious months of remission in some people with colorectal cancer that has spread to other tissues, new research shows. While both drugs are synthetic antibodies, they take distinctly different approaches to fighting the malignancy.
In one trial, scientists show for the first time that patients can benefit from a compound that blocks blood vessel growth, also called angiogenesis, and thus disrupts a tumor’s nutrient supply.
Log in
Subscribers, enter your e-mail address for full access to the Science News archives and digital editions.